(Total Views: 494)
Posted On: 03/23/2021 11:26:50 PM
Post# of 151815
Good points about RO, I tend to agree, and non-mITT is a valid point as well, but not everyone said CD12 would be a slam dunk.. you heard what you wanted to hear, if that's what you heard ; )
Dex+LLMab isnt necessarily contraindicated; there was shown benefit over and possibly as combo with Dex, no?
The population with the most dramatic recoveries, ECMO etc, wasn't the focus of CD12, ergo that couldn't be shown. People were spazzing out about the trial taking too long, not doing 75% analysis (making trial longer), now possible trial participants should have been rejected if they weren't on ECMO? Maybe you should apply to run the trials.. not sure I'd want to see that.
What Patterson doesn't have is Leronlimab. Renders him fairly moot.
Dex+LLMab isnt necessarily contraindicated; there was shown benefit over and possibly as combo with Dex, no?
The population with the most dramatic recoveries, ECMO etc, wasn't the focus of CD12, ergo that couldn't be shown. People were spazzing out about the trial taking too long, not doing 75% analysis (making trial longer), now possible trial participants should have been rejected if they weren't on ECMO? Maybe you should apply to run the trials.. not sure I'd want to see that.
What Patterson doesn't have is Leronlimab. Renders him fairly moot.
(1)
(0)Scroll down for more posts ▼
